Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/111837
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia
Author: Ballen, K.
Woolfrey, A.
Zhu, X.
Ahn, K.
Wirk, B.
Arora, M.
George, B.
Savani, B.
Bolwell, B.
Porter, D.
Copelan, E.
Hale, G.
Schouten, H.
Lewis, I.
Cahn, J.
Halter, J.
Cortes, J.
Kalaycio, M.
Antin, J.
Aljurf, M.
et al.
Citation: Biology of Blood and Marrow Transplantation, 2012; 18(9):1446-1454
Publisher: Elsevier
Issue Date: 2012
ISSN: 1083-8791
1523-6536
Statement of
Responsibility: 
Karen K. Ballen, Ann E. Woolfrey, Xiaochun Zhu, Kwang Woo Ahn, Baldeep Wirk ... Mary M. Horowitz ... et al.
Abstract: Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.
Keywords: Transplantation; PV; ET
Rights: © 2012 American Society for Blood and Marrow Transplantation
RMID: 0030034497
DOI: 10.1016/j.bbmt.2012.03.009
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.